KDR and hepatocellular carcinoma: For example, AZD7121, an orally active vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, suppresses tumor growth by inducing cellular senescence and exhibits limited toxicity in phase II clinical trials of advanced HCC patients [40].